Relationship between Changes of the Value of s-AST/ALT and Serologic Markers for Hepatitis B Virus during Anti-tuberculosis (HRE) Treatment |
Kyung Sun Son1, Nam Jae Kim1, Ji Won Suhr1, Yeon Chae Jeong1, Ju Ock Kim1, Sun Young Kim1, Kyoung Joo Rhee2 |
1Department of Internal Medicine, College of Medicine, Chungnam National University, Chungnâm, Koreae 2Department of Internal Medicine, Daejeon Eulji Hospital, Daejeon, Koreae |
항결핵 삼제요법(HRE) 중 혈청 AST/ALT의 상승과 B형 간염의 혈청학적 지표와의 관계 |
손경선1, 김남재1, 서지원1, 정연채1, 김주옥1, 김선영1, 이경주2 |
|
|
Abstract |
A clinical study was performed in 272 patients who had pulmonary tuberculosis to evaluate the relationship between changes of the value of s.AST / ALT and serologic markers for hepatitis B virus during anti-tuberculous treatment with three drug regimen of isoniazid (INH), rifampicin (RFP), and ethambutol (EMB).
Results were as follows:
1) Among the 272 pulmonary tuberculosis patients, 54 patients had HBsAg (+), 82 patients had HBsAb (+), and 136 patients had HBsAg (-) & HBsAb (-).
2) During the antituberculous chemotherapy, s.AST/ALT were elevated in 48 (17.6%) patients.
Among the 54 patients with HBsAg, 10 patients (18.5%) showed elevation of s.AST/ ALT; among 83 patients with HBsAb, 13 patients (15.9%) showed s.AST/ ALT elevation; and among 136 patients without HBsAg & HBsAb, 25 patients (18.4%) showed s.AST/ ALT elevation.
3) There was no statistical significance between the time and degree of s.AST/ ALT elevation.
4) Treatment interruption occurred in 2 patients due to the marked elevation of s.AST/ ALT . One patient was HBsAg.positive and the other was negative in HBsAg & HBsAb. As a result of this study, we concluded that the relationship between changes of the value of s-AST / ALT and serologic markers for hepatitis B virus was not significantly different among each group of patients with HBsAg, HBsAb, and without HBsAg & HBsAb during antituberculous treatment with isoniazid, rifampicin, and ethamutol (HRE) regimen. |
|